Sign In
Buy DBVT
$13.63
-0.230 (-1.66%)
At Close: Jul 24, 2026
DBV Technologies Press Release Confirms FDA AdCom Panel For Viaskin Peanut Candidate As May 15, 2020
12:00am, Friday, 21'st Feb 2020Perceptive Advisors Llc Buys Agios Pharmaceuticals Inc, Provention Bio Inc, Quotient, Sells ...
12:00am, Wednesday, 19'th Feb 2020DBV Technologies to Present at the SVB Leerink 9th Annual Global Healthcare Conference
12:00am, Monday, 10'th Feb 2020Bio Roundup: POTUS on Prices, a16z's Fund, Aimmune's Approval & More
12:48pm, Friday, 07'th Feb 2020
The president’s State of the Union address was wide-ranging, as they tend to be, but those who tuned in heard mention of two hot health policy topics:
3 Biotechnology Stocks Moving In Tuesday's Pre-Market Session
12:00am, Tuesday, 04'th Feb 2020Aimmune's 'First-Of-Its-Kind' Peanut Allergy Drug Receives FDA Approval
08:53pm, Saturday, 01'st Feb 2020
Shares of biopharma Aimmune Therapeutics Inc (NASDAQ: AIMT ) advanced strongly in after-hours trading Friday following a positive FDA verdict for Aimunne's peanut allergy drug. 9-Year Wait Ends The FD
The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance
02:26pm, Thursday, 30'th Jan 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 29) 10X Genomics Inc (NASDAQ: TXG ) Agile Therapeutics
DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares For $125M Worth of Company's ADS
12:00am, Wednesday, 29'th Jan 202020 Biotechnology Stocks Moving In Tuesday's After-Market Session
12:00am, Tuesday, 21'st Jan 2020
Rafaèle Tordjman launches JEITO CAPITAL, a new French and independent investment investor dedicated to biotech and biopharma. The launch is completed by the closing of JEITO I fund's with the support
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
12:00am, Wednesday, 15'th Jan 2020Apellis Pharmaceuticals Phase 3 Success, And Other News: The Good, Bad, And Ugly Of Biopharma
03:27pm, Friday, 10'th Jan 2020
Apellis Pharmaceuticals' PEGASUS trial produced positive data. DBV Technologies saw success in a peanut allergy trial. Mylan recalled some bad medicine.
